Gepirone (Exxua): New Antidepressant FDA Approved for MDD
On Sep 28, 2023: Fabre-Kramer Pharmaceuticals Announcesd the FDA Approval of EXXUA™, the Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder…
On Sep 28, 2023: Fabre-Kramer Pharmaceuticals Announcesd the FDA Approval of EXXUA™, the Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.